You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Investigators have developed an approach called RAMP-Seq in which targeted radiation of a suspicious lesion vastly increase levels ctDNA, aiding detection and allowing genotyping.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.
A new analysis has provided evidence that adjuvant lung cancer immunotherapy benefits those with lingering ctDNA, but not necessary those without.
The deal comes on the heels of a colorectal cancer-focused drug-discovery alliance that the German companies formed in early 2019.
The funds will support the companies' efforts to develop tests for predicting NSCLC patients' response to immunotherapy.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
Palmetto has expanded the local coverage determination for the Guardant360 liquid biopsy assay to be used with the majority of advanced solid tumors.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.